sftd
Letairis™ (ambrisentan), FDA-Approved for Pulmonary Arterial Hypertension
Filed in archive News , Treatment by Gloria Gamat on June 17, 2007
letairis_ambrisentan.jpg
Manufactured by Gilead Sciences, Inc., Letairis™ (ambrisentan) has recently been approved by the FDA for the treatment of pulmonary arterial hypertension.

Pulmonary arterial hypertension is a rare, life-threatening condition characterized by continuous high blood pressure within the arteries of the lungs.

[In pulmonary arterial hypertension, the small arteries in the lungs become narrowed or blocked, and the heart must work harder to pump the blood through them.

Over time, the overworked heart muscle may become weak and lose its ability to pump enough blood through the lungs.

Symptoms include shortness of breath, fatigue, chest pain, dizzy spells and fainting. About 100,000 people in the United States have pulmonary arterial hypertension.]

According to John Jenkins, M.D., director of FDA's Office of New Drugs:

"Letairis represents a valuable addition to the treatment alternatives for this orphan disease. Letairis is similar to an existing drug, but offers the potential for fewer drug interactions."


Not previously approved in the Unites States, Letairis™ was granted a priority review by FDA and was granted orphan drug status because it treats a rare disease and meets other criteria.

Letairis™ will be available in five-milligram and 10-milligram once-daily tablets.

Find more details from the press releases at FDA and Gilead Sciences, Inc.

Permalink: Letairis™ (ambrisentan), FDA-Approved for Pulmonary Arterial Hypertension
Tags: Letairis™  ambrisentan  pulmonary  arterial  hypertension  2007  arterial+hypertension  pulmonary+arteria 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/76139
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for Letairis™ (ambrisentan), FDA-Approved for Pulmonary Arterial Hypertension:

  • Currently 4.25/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 4.25 out of 4 vote(s) cast.
Subscribe
Share It
Popular posts from our other blogs:
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!